ÂÜÀòÂÒÂ×

With more than 25 years’ experience, Bob was previously Vice President of Translational Research and Development at ImmunoGen Inc., where he was responsible for all early-stage ADC development programs and gained further experience in directing the clinical pharmacology, biomarkers, pharmacology and toxicology departments. While at ImmunoGen, Bob was responsible for bringing eight of ImmunoGen’s candidate ADC products into development and was the research lead for Kadcyla